Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

DSpace Repository

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Author: Lonial, Sagar; Lee, Hans C.; Badros, Ashraf; Trudel, Suzanne; Nooka, Ajay K.; Chari, Ajai; Abdallah, Al-Ola; Callander, Natalie; Lendvai, Nikoletta; Sborov, Douglas; Suvannasankha, Attaya; Weisel, Katja; Karlin, Lionel; Libby, Edward; Arnulf, Bertrand; Facon, Thierry; Hulin, Cyrille; Kortum, K. Martin; Rodriguez-Otero, Paula; Usmani, Saad Z.; Hari, Parameswaran; Baz, Rachid; Hang Quach; Moreau, Philippe; Voorhees, Peter M.; Gupta, Ira; Hoos, Axel; Zhi, Eric; Baron, January; Piontek, Trisha; Lewis, Eric; Jewell, Roxanne C.; Dettman, Elisha J.; Popat, Rakesh; Esposti, Simona Degli; Opalinska, Joanna; Richardson, Paul; Cohen, Adam D.
Tübinger Autor(en):
Weisel, Katja
Published in: Lancet Oncology (2020), Bd. 21, H. 2, S. 207-221
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(19)30788-0
ISSN: 1474-5488
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)